logoTry Persana

Pardes Biosciences - Company Overview, Founder, CEO, Funding & Investment Details

Complete information about Pardes Biosciences including founder details, CEO information, total funding raised, headquarters location, team size, and recent investment rounds.

Pardes Biosciences company logo

We Solve Pandemic-Sized Problems.

Pardes is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines.

HeadquartersCarlsbad, CA, US
Team size1-50
Founded2020

What is Pardes Biosciences? - Company Overview & Details

Pardes Biosciences is Pardes is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. Founded in 2020, the company is headquartered in Carlsbad, CA, US.

Who Founded Pardes Biosciences?

Pardes Biosciences is led by CEO Thomas G. Wiggans.

Who are the Key Executives at Pardes Biosciences? - Leadership Team

Pardes Biosciences is led by experienced executives in key positions:

Chief Executive Officer (CEO) of Pardes Biosciences

Thomas G. WiggansCEO

Chief Technology Officer (CTO) of Pardes Biosciences

CTO

About Thomas G. Wiggans - CEO of Pardes Biosciences

Thomas G. Wiggans serves as the Chief Executive Officer of Pardes Biosciences, leading the company's strategic vision and operations.

Pardes Biosciences Company Details & Key Information

Where is Pardes Biosciences located?

Pardes Biosciences is headquartered in Carlsbad, CA, US.

How many employees does Pardes Biosciences have?

Pardes Biosciences has 1-50 employees.

When was Pardes Biosciences founded?

Pardes Biosciences was founded in 2020.

Pardes Biosciences Official Website

How much funding has Pardes Biosciences raised?

Pardes Biosciences has raised $75 Million across 2 funding rounds. The most recent funding was completed on 2022-01-27.

Funding Overview

Pardes raised $75 million in a Post IPO equity round led by Foresite Capital.

$75 Million
Total Funding Raised
2
Funding Rounds
2022-01-27
Latest Round

Pardes Biosciences Funding History

Post IPO equity
2022-01-27
$75 Million

Who are the key investors in Pardes Biosciences?

Pardes Biosciences is backed by 1 key investors including Foresite Capital. These investors focus on sectors.

Pardes Biosciences Investor Overview

1
Key Investors
0
Focus Areas
0
Notable Investments

Complete List of Pardes Biosciences Investors

Foresite Capital

What sectors do Pardes Biosciences investors focus on?

The investors backing Pardes Biosciences primarily focus on sectors.

Featured Investor: Foresite Capital

Foresite Capital

Notable Investments:

What are Pardes Biosciences's future plans?

Future Plans Information Not Available

Detailed information about Pardes Biosciences's future plans and strategic initiatives is not currently available in our database.

What are the latest news about Pardes Biosciences?

Pardes Biosciences has 2 recent news updates covering key business developments and market activities.

Pardes Biosciences News Overview

2
Recent Articles
Active
Media Coverage
2023-08-07
Latest Update

What is Pardes Biosciences in the news for?

Pardes Biosciences is currently featured in news for Medi Corp acquires Pardesbio. and other significant business developments.

Recent News Articles About Pardes Biosciences

Article 1
2023-08-07

Medi Corp acquires Pardesbio.

Pardes Biosciences is being investigated for the adequacy of price and process in its proposed sale to MediPacific, Inc.

businesswire.com
Read News
Article 2
2023-07-24

Midpac acquires Pardesbio.

Brodsky & Smith is investigating whether the Pardes Board breached its fiduciary duties concerning the acquisition by MediPacific, Inc.

globenewswire.com
Read News

Pardes Biosciences FAQ - Frequently Asked Questions About Founder, CEO, Funding & Company Details

Find answers to the most common questions about Pardes Biosciences including information about founders, CEO, funding history, investors, headquarters location, and company details. 16 frequently asked questions covering key information about the company.

Pardes Biosciences Questions & Answers - Company Information

Q1

What is Pardes Biosciences?

Pardes is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines.

Q2

Who founded Pardes Biosciences?

Pardes Biosciences is led by CEO Thomas G. Wiggans.

Q3

Who is the CEO of Pardes Biosciences?

The CEO of Pardes Biosciences is Thomas G. Wiggans.

Q4

How much funding has Pardes Biosciences raised?

Pardes Biosciences has raised a total of $$75 Million across 2 funding rounds. The most recent funding was completed on 2022-01-27.

Q5

Who are the investors in Pardes Biosciences?

Pardes Biosciences's key investors include Foresite Capital.

Q6

Where is Pardes Biosciences headquartered?

Pardes Biosciences is headquartered in Carlsbad, CA, US.

Q7

When was Pardes Biosciences founded?

Pardes Biosciences was founded in 2020.

Q8

How many employees does Pardes Biosciences have?

Pardes Biosciences has 1-50 employees.

Q9

What is Pardes Biosciences's official website?

You can visit Pardes Biosciences's official website at http://www.pardesbio.com.

Q10

What was Pardes Biosciences's latest funding round?

Pardes Biosciences's latest funding round was a Post IPO equity round of $$75 Million completed on 2022-01-27.

Q11

Who is founder?

Thomas G. Wiggans

Q12

What does the company do?

Pardes is a clinical-stage biopharmaceutical company focused on solving pandemic-sized problems, particularly COVID-19.

Q13

How much funding?

$75 Million

Q14

Latest funding date?

2022-01-27

Q15

Who are the investors?

Foresite Capital

Q16

Latest news?

Pardes Biosciences is being investigated for the adequacy of price and process in its proposed sale to MediPacific, Inc. Brodsky & Smith is investigating whether the Pardes Board breached its fiduciary duties concerning the acquisition by MediPacific, Inc.

More Information About Pardes Biosciences

For additional details about Pardes Biosciences, including the latest news, funding updates, and company developments, explore our comprehensive company database. Find information about startup funding, company valuations, executive leadership, and business intelligence data.